Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

You may not qualify if:

• The participant was previously included in this study.
• Fewer than 7 disintegration half-lives had elapsed between the participant's last procedure (therapeutic or diagnostic) involving a radioisotope and Visit 2 (altropane SPECT imaging).
• Including participation in this study, the participant's total exposure to radiation during medical procedures/tests in the past year would have exceeded 50 mSv.
• The participant had participated in an investigational drug or device clinical trial within 30 days before the date of informed consent.
• The participant had any clinically significant or unstable physical or psychological illness, structural brain abnormality, abnormal laboratory results, or abnormal ECG (based on medical history or physical examination at Screening), as determined by the Principal Investigator, that would interfere with study participation.
• The participant had any history of drug or alcohol abuse in the 2 years prior to the date of informed consent.
• The participant had a positive urine screen for drugs of abuse at Screening.
• The participant was a pregnant or breast-feeding female, or was a female of child-bearing potential that was not using appropriate birth control.
• The participant was unable to lie supine for 1 hour.
• The participant had any thyroid disease other than adequately treated hypothyroidism.
• The participant had known or suspected allergy/hypersensitivity to any ingredient in Altropane or to the thyroid blocking medication to be used before imaging.
• The participant was taking any of the medications/treatments listed in the protocol as disallowed and could not or would not discontinue use at least 12 hours prior to SPECT exam.
• The participant was referred to DaTscan imaging for evaluation of possible cognitive impairment including dementia.